Gland Pharma Limited (GLAND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gland Pharma Limited (GLAND) has a cash flow conversion efficiency ratio of 0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs5.93 Billion ≈ $64.16 Million USD) by net assets (Rs95.63 Billion ≈ $1.03 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GLAND days of operational coverage to measure how many days the company can operate on defensive assets alone.
Gland Pharma Limited - Cash Flow Conversion Efficiency Trend (2017–2026)
This chart illustrates how Gland Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gland Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gland Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bestechnic (Shanghai) Co. Ltd. A
SHG:688608
|
0.042x |
|
Aris Mining Corporation
NYSE MKT:ARMN
|
0.070x |
|
HLA GROUP CORP LTD
SHG:600398
|
0.126x |
|
Marketech International Corp
TW:6196
|
0.095x |
|
Bohai Leasing Co Ltd
SHE:000415
|
0.138x |
|
Envista Holdings Corp
NYSE:NVST
|
0.025x |
|
Jiangxi Zhengbang Technology Co Ltd
SHE:002157
|
0.025x |
|
Vallourec
PA:VK
|
0.033x |
Annual Cash Flow Conversion Efficiency for Gland Pharma Limited (2017–2026)
The table below shows the annual cash flow conversion efficiency of Gland Pharma Limited from 2017 to 2026. For the full company profile with market capitalisation and key ratios, see Gland Pharma Limited market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs103.58 Billion ≈ $1.12 Billion |
Rs12.31 Billion ≈ $133.16 Million |
0.119x | +18.92% |
| 2025-03-31 | Rs91.51 Billion ≈ $989.62 Million |
Rs9.15 Billion ≈ $98.92 Million |
0.100x | -12.51% |
| 2024-03-31 | Rs87.24 Billion ≈ $943.45 Million |
Rs9.97 Billion ≈ $107.80 Million |
0.114x | +149.85% |
| 2023-03-31 | Rs79.59 Billion ≈ $860.71 Million |
Rs3.64 Billion ≈ $39.36 Million |
0.046x | -58.61% |
| 2022-03-31 | Rs71.58 Billion ≈ $774.07 Million |
Rs7.91 Billion ≈ $85.52 Million |
0.110x | +7.81% |
| 2021-03-31 | Rs59.03 Billion ≈ $638.41 Million |
Rs6.05 Billion ≈ $65.42 Million |
0.102x | -46.69% |
| 2020-03-31 | Rs36.46 Billion ≈ $394.33 Million |
Rs7.01 Billion ≈ $75.80 Million |
0.192x | +196.98% |
| 2019-03-31 | Rs28.62 Billion ≈ $309.51 Million |
Rs1.85 Billion ≈ $20.03 Million |
0.065x | -22.80% |
| 2018-03-31 | Rs24.10 Billion ≈ $260.67 Million |
Rs2.02 Billion ≈ $21.86 Million |
0.084x | -63.22% |
| 2017-03-31 | Rs20.90 Billion ≈ $226.01 Million |
Rs4.76 Billion ≈ $51.53 Million |
0.228x | -- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more